Colchicine effects on treatment of COVID-19

Efficacy and safety of colchicine on clinical improvement in patients with COVID-19: A randomized, double blind clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190804044429N5

Enrollment

110

Registered

2021-02-18

Start date

2021-02-22

Completion date

Unknown

Last updated

2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 pneumonia. COVID-19, virus identified

Interventions

Intervention 1: Intervention group: Medication regimen including 250 mcg interferon beta 1 b subcutaneous injection every other day for at least 3 doses plus remdesivir 200 mg as first dose then 100 m

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria are adults over the age of 18 with a diagnosis of COVID-19 based on clinical criteria (presence of any symptoms of cough, shortness of breath, fever, and CT scan of the lung for evidence of involvement consistent with COVID-19 infection) or PCR and Had clinical symptoms of COVID-19 within two weeks

Exclusion criteria

Exclusion criteria: Pregnancy and lactation Severe hepatic insufficiency (Child-pugh C) Renal insufficiency (GFR less than 30 ml/min) Allergy history of colchicine Thrombocytopenia (Platelets less than 100,000 /mm3) Not consent

Design outcomes

Primary

Measure	Time frame
Respiratory rate. Timepoint: Before intervention and daily during the study. Method of measurement: physical exam.;Blood oxygen saturation. Timepoint: Before intervention and daily during the study. Method of measurement: pulse oximeter.;Fever recovery. Timepoint: Before intervention and daily during the study. Method of measurement: thermometer.;Therapeutic regimen safety. Timepoint: Daily during the study. Method of measurement: Incidence of any side effects.;CRP. Timepoint: before intervention and then three times weekly during the study. Method of measurement: CRP laboratory kite.;Lymphocyte count. Timepoint: before intervention and then daily during the study. Method of measurement: Cell blood count test.	—

Measure

Time frame

Respiratory rate. Timepoint: Before intervention and daily during the study. Method of measurement: physical exam.;Blood oxygen saturation. Timepoint: Before intervention and daily during the study. Method of measurement: pulse oximeter.;Fever recovery. Timepoint: Before intervention and daily during the study. Method of measurement: thermometer.;Therapeutic regimen safety. Timepoint: Daily during the study. Method of measurement: Incidence of any side effects.;CRP. Timepoint: before intervention and then three times weekly during the study. Method of measurement: CRP laboratory kite.;Lymphocyte count. Timepoint: before intervention and then daily during the study. Method of measurement: Cell blood count test.

—

Secondary

Measure	Time frame
Hospital stay duration. Timepoint: End of treatment. Method of measurement: Patient file.;Mortality rate. Timepoint: Daily during the study. Method of measurement: patient file.	—

Countries

Iran (Islamic Republic of)

Contacts

Public Contact??????? ?????????

Mazandaran University of Medical Sciences

ghazaeianm@gmail.com+98 11 3334 3011

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026